We have previously shown that biglycan positively modulates poorly differentiated and biglycan-expressing MG63 osteosarcoma cell growth through an IGF-IR/β-catenin/ERK1/2 signaling conduit [30]. This evidence concerns the gene MAPK3 and osteosarcoma.